The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.

Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human ...

Brelovitug has previously received Orphan and PRIME designation from the European Medicines Agency.

A revolutionary new treatment for breast cancer has shown the ability to eliminate small breast tumors and significantly ...

A Virginia Senate subcommittee has advanced a bill that would help fund clinical trials involving veterans and “breakthrough therapies” as designated by the Food and Drug Administration ...

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...

The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...

What You Need to Know The global hydrogen water market is projected to grow from USD 2.5 billion in 2024 to USD 4.35 billion ...